Fukuoka, Japan

Masami Tanaka

USPTO Granted Patents = 3 


Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Kodaira, JP (1990)
  • Fukuoka, JP (2014 - 2015)

Company Filing History:


Years Active: 1990-2015

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Masami Tanaka: Innovator in Cancer Research

Introduction

Masami Tanaka is a prominent inventor based in Fukuoka, Japan. She has made significant contributions to the field of cancer research, particularly in the development of novel cancer markers. With a total of three patents to her name, her work is paving the way for advancements in cancer evaluation and treatment.

Latest Patents

Tanaka's latest patents focus on a cancer marker and methods for evaluating cancer using this marker. The present invention provides a novel cancer marker for assessing the onset, preclinical stage, clinical stage, or prognosis of cancer in a subject. This cancer marker includes at least one miRNA selected from hsa-miR-92 and hsa-miR-494, specifically used for cancers excluding breast cancer. The evaluation method involves detecting the expression level of the cancer marker in a biological sample collected from a subject, which is crucial for determining the possibility of cancers other than breast cancer.

Career Highlights

Throughout her career, Masami Tanaka has worked with notable organizations such as NEC Corporation and Tokyo Medical University. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Tanaka has collaborated with esteemed colleagues, including Masahiko Kuroda and Kosuke Oikawa. These partnerships have enhanced her research efforts and expanded the impact of her innovations in cancer evaluation.

Conclusion

Masami Tanaka's work in cancer research exemplifies the importance of innovation in medical science. Her patents and collaborations are instrumental in advancing the understanding and evaluation of cancer, ultimately contributing to better patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…